Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, announced the launch of ZetaOmics, the computational biology module of its multi-agentic AI co-scientist platform, withZeta.ai. The new platform introduces an autonomous “Computational Biologist” agent designed to perform end-to-end bioinformatics and multi-omic analysis across various cancer types. Initially available through an early-access program for select academic, industry, and company collaborators, ZetaOmics is intended to automate complex research workflows while embedding domain-specific intelligence to improve analytical rigor and reproducibility.
According to the company, ZetaOmics combines 14 specialized tools that can autonomously design, execute, and validate biological analyses, detect potential flaws in experimental design, and generate publication-quality results with a complete audit trail. Lantern stated that the platform expands withZeta.ai’s commercial opportunity beyond rare cancers by targeting academic medical centers, biotechnology and pharmaceutical companies, cancer centers, and contract research organizations through subscription-based offerings and strategic collaborations.
The launch of ZetaOmics represents a significant step in Lantern's strategy to monetize its AI capabilities. The withZeta.ai platform, which is now commercially available as a subscription-based research platform, offers a new revenue stream for the company. Lantern Pharma operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas.
Lantern Pharma is a clinical-stage precision oncology company leveraging AI, machine learning, and its proprietary RADR platform to transform the development of cancer therapies. Its clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
The announcement underscores the growing role of AI in drug discovery and development. By automating complex bioinformatics workflows, ZetaOmics aims to reduce the time and cost associated with cancer research while enhancing data quality and reproducibility. The platform's early-access program will allow researchers to test its capabilities and provide feedback, potentially leading to broader adoption in the scientific community.
For more information, visit the full press release here. Additional details about Lantern Pharma are available in the company’s newsroom at https://ibn.fm/LTRN.
